Drugs that contain Risperidone
1. List of Perseris Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10406160 | INDIVIOR INC | Sustained release small molecule drug formulation |
Jun, 2026
(3 years from now) | |
| US10058554 | INDIVIOR INC | Sustained release small molecule drug formulation |
Sep, 2026
(3 years from now) | |
| US9597402 | INDIVIOR INC | Sustained release small molecule drug formulation |
Sep, 2026
(3 years from now) | |
| US11110093 | INDIVIOR INC | Sustained release small molecule drug formulation |
Nov, 2026
(3 years from now) | |
| US10010612 | INDIVIOR INC | Sustained delivery formulations of risperidone compounds |
Feb, 2028
(4 years from now) | |
| US9180197 | INDIVIOR INC | Sustained delivery formulations of risperidone compounds |
Feb, 2028
(4 years from now) | |
| US9186413 | INDIVIOR INC | Sustained delivery formulations of risperidone compounds |
Feb, 2028
(4 years from now) | |
| US10376590 | INDIVIOR INC | Sustained delivery formulations of risperidone compound |
Feb, 2028
(4 years from now) | |
| US11013809 | INDIVIOR INC | Sustained delivery formulations of risperidone compound |
Feb, 2028
(4 years from now) | |
Market Authorisation Date: 27 July, 2018
Treatment: Method of treating schizophrenia; Administration of risperidone; Treating schizophrenia; Treatment of schizophrenia
Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
PERSERIS KIT family patents
17
United States
6
Japan
4
European Union
3
Spain
2
Denmark
2
Canada
2
Mexico
2
Australia
2
New Zealand
2
China
1
Israel
1
Hong Kong
1
Argentina
1
Brazil
1
Poland
1
Austria
1
Taiwan, Province of China
2. List of Rykindo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10406161 | SHANDONG LUYE | Risperidone sustained release microsphere composition |
Apr, 2032
(9 years from now) | |
| US10098882 | SHANDONG LUYE | Risperidone sustained release microsphere composition |
Apr, 2032
(9 years from now) | |
| US9532991 | SHANDONG LUYE | Risperidone sustained release microsphere composition |
Apr, 2032
(9 years from now) | |
| US9446135 | SHANDONG LUYE | Risperidone sustained release microsphere composition |
Apr, 2032
(9 years from now) | |
| US11110094 | SHANDONG LUYE | Risperidone sustained release microsphere composition |
Apr, 2032
(9 years from now) | |
Market Authorisation Date: 13 January, 2023
Treatment: Treatment of schizophrenia in adults
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic